TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01655953

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High NaCl + KHCO3
Description: 7.7 mmol Na/kgBW/d + 90 mmol KHCO3

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High NaCl + KHCO3
Description: 7.7 mmol Na/kgBW/d + 90 mmol KHCO3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control: high NaCl
Description: 7.7 mmol Na/kgBW/d

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control: high NaCl
Description: 7.7 mmol Na/kgBW/d
Study: NCT04596839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir INN 100 mg lyophilized powder for infusion

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection
Study: NCT03711422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40mg daily
Study: NCT03161041

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery combined with HIPEC
Description: Procedure/Surgery: Cytoreductive surgery combined with HIPEC (Oxaliplatin 360 mg/m2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
Description: bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
Study: NCT00447096

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Repetitive transcranial magnetic stimulation (rTMS).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Repetitive transcranial magnetic stimulation (rTMS).
Study: NCT02136459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small Tube size
Description: An endotracheal tube of size 6.5 in females and 7.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Large Tube size
Description: An endotracheal tube of size 7.5 in females and 8.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
Study: NCT03065686

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: identification of genetic factors
Description: Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
Study: NCT04974229

Intervention type: OTHER
Intervention: In line with the Dutch guideline for non-specific low back pain, Standard usual care for non-specific low back pain was applied.
Description: In line with the Dutch guideline for non-specific low back pain, Standard usual care or non-specific low back pain was applied.
Study: NCT02277275

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA
Description: Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided to the other two arms for six months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided to the other two arms for six months
Study: NCT01967680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-sedation for intubated, mechanically ventilated patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Controlgroup, sedation with daily wake-up trial
Study: NCT01814410

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous ethanol placebo plus nicotine infusions
Description: nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous ethanol 40mg% plus nicotine infusions
Description: nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous ethanol 100mg% plus nicotine infusions
Description: nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
Study: NCT01810562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific treatment in addition to standard stroke care
Description: Stimulation of both the affected side and not affected side. Treatment twice per day for three months. Unperturbed side always stimulated first.~Isstimulering achieved by an ice cube melted on each of the affected ektremitetene evenly distributed.~Brushing on thin clothing or directly on the skin, 10 times rapidly for each location. On the back of m. deltoideus from right to left side of the body, laterally along the humerus, frontally, along the radius / ulna laterally, frontal and dorsal palm, along the femur first laterally and frontally, along the tibia / fibula laterally, frontally and the footplate dorsal side.~Scrolling with spiked ball over the same area as brushing for two minutes evenly.~Firm pressure for two minutes evenly in the same area.
Study: NCT00091468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Description: double-blind phase: 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks open label phase: 5mg for 1 week, 10mg. for 2 weeks, 15mg. for 23 weeks taper down: 10mg. for 2 weeks, 5mg. for 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal patch
Description: placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks
Study: NCT03128450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human neural stem cell
Description: human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel
Study: NCT04194489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMF Connect
Description: The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
Study: NCT02402946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02020369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIIa (Recombinant)
Description: A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIIa (Recombinant)
Description: A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX
Study: NCT04064203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: 50 grams OGTT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: 50 grams OGTT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clamp experiment
Description: insulin-induced hypoglycaemic clamp followed by an 50 grams OGTT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clamp experiment
Description: insulin-induced hypoglycaemic clamp followed by an 50 grams OGTT
Study: NCT02751112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Predictor' kit
Description: Realization of the Predictor' kit on the blood of donor of HSC, in the frame of a graft, to predict a aGvH reaction on recipient patient.
Study: NCT02397941

Intervention type: OTHER
Intervention: Ultrasound
Description: ultrasound measures

Intervention type: OTHER
Intervention: Ultrasound
Description: ultrasound measures

Intervention type: OTHER
Intervention: Ultrasound
Description: ultrasound measures
Study: NCT03711422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 160mg for 3 days every 3 weeks
Study: NCT01000987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 1mg/day or 2 mg/day Subjects are at steady state medication levels. They are participating during the 4-week medication period of our ongoing study, NCT00580645.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00687986

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiotherapy
Description: Either 3 fractions of 20 Gray or 5 fractions of 12 Gy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary surgery
Description: an anatomical surgical resection with lymph node dissection
Study: NCT01439243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept®
Description: 10 mg Tablet
Study: NCT01289327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation with Propofol or Midazolam+Alfentanil for FFB
Description: Sedation was started with intravenous injection of a bolus of 2-4 mg midazolam and 0.5 mg alfentanil or 20-50 mg propofol. It was maintained with intermittent boluses of 1-3 mg intravenous midazolam or 0.5 mg intravenous alfentanil, according to clinical judgment, or with boluses of 10-20 mg intravenous propofol, administered at short intervals (\~2 minutes) or according to clinical judgment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation with Propofol or Midazolam+Alfentanil for FFB
Description: Sedation was started with intravenous injection of a bolus of 2-4 mg midazolam and 0.5 mg alfentanil or 20-50 mg propofol. It was maintained with intermittent boluses of 1-3 mg intravenous midazolam or 0.5 mg intravenous alfentanil, according to clinical judgment, or with boluses of 10-20 mg intravenous propofol, administered at short intervals (\~2 minutes) or according to clinical judgment.
Study: NCT01411319

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lattice Extreme Ablative Dose Radiation Therapy
Description: 12 - 14 Gy dose pipes in 1 fraction to the multiparametric MRI defined gross tumor volumes (GTV) on Day 1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard IMRT
Description: 76 Gy in 38 fractions (2 Gy daily) of Standard Intensity-modulated radiation therapy (IMRT) starting on Day 2 for 7.5 weeks.
Study: NCT04624048

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 survey
Description: Participants should complete a survey to analyze the impact of COVID-19 on University population.
Study: NCT01255904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloral Hydrate
Description: Oral chloral hydrate 50 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine 3 mcg/kg
Study: NCT03834324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES
Description: Functional Electrical Stimulation during cycling with Virtual Reality Feedback
Study: NCT02946853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrioventricular junctional (AVJ) ablation
Description: RF energy delivery to AV node to create complete AV block

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac resynchronization therapy - defibrillator
Description: Insertion of device capable of providing biventricular pacing and cardiac defibrillation
Study: NCT01255904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral placebo
Description: Oral saline administered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intranasal placebo
Description: Intranasal saline administered
Study: NCT02154932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 doses 400 microgram misoprostol
Description: 2 doses 400 microgram misoprostol, 3 and 1 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single dose misoprostol
Description: 1 dose, 1 hours, prior surgery
Study: NCT04192721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Based Group Counseling
Description: * Relaxation techniques~* Providing personal development books~* Sharing the factors affecting the situation defined as depression (brainstorming)~* Explaining the link between depressive symptoms, thoughts, feelings, and behaviors~* Explaining automatic thoughts~* Application of relaxation techniques; deep-breathing exercises~* Identifying alternative thoughts~* Explaining the correlation between alternative thoughts and mood~* Introduction of the Automatic-Thought Registration Form and distribution to students~* Describing the effects of depression on social interaction~* Explaining activities that could be done individually and with the group~* Distribution of the activity list to students~* Description of ways of coping with stress~* Determination of individual stressors and their effects~* Planning for the future: preventing depression~* Discussion of assumptions/expectations about life~* Homeworks related to session contents
Study: NCT03607877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer walking training and positive education
Description: Intervention: (1)Positive education: Six psychosocial sessions were designed to enhance elders' positive emotion, motivation and self-efficacy to walk.~(2) Pedometer walking training: walk at least 30 minutes per day and at least three times per week with family support and exercise companions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer walking with training
Description: Intervention:walk at least 30 minutes per day and at least three times per week with family support and exercise companions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pedometer walking
Description: Intervention: pedometer walking at least 30 minutes per day and at least three times per week
Study: NCT05734820

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HD- colonoscopy
Description: HD-colonoscopy performed by an expert or non-expert endoscopist. All lesions will be recorded, assessed, and removed for histological analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HD- colonoscopy
Description: HD-colonoscopy performed by an expert or non-expert endoscopist. All lesions will be recorded, assessed, and removed for histological analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HD-colonoscopy assisted by AI
Description: HD-colonoscopy with AI-assisted polyp detector. New polyps detected by AI will be recorded, removed, and studied.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HD-colonoscopy assisted by AI
Description: HD-colonoscopy with AI-assisted polyp detector. New polyps detected by AI will be recorded, removed, and studied.
Study: NCT01214889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENTAXIM™: DTacP IPV//PRP~T combined vaccine
Description: 0.5 mL, intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine
Description: 0.5 mL of each vaccine; intramuscular
Study: NCT01997034

Intervention type: BEHAVIORAL
Intervention: Intensive Lifestyle Intervention
Description: The included subjects has previously participated in the Intensive Lifestyle Intervention intervention at Ubberup Folk High School. This intervention includes daily exercise and a hypocaloric diet (app. -700KCal/day) for 10-14 weeks. Furthermore theoretical and practical education within e.g. Nutrition, exercise and motivational psychology.
Study: NCT03793569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer discussion group
Description: Subjects in the intervention group will be asked to attend one peer group between four and eight weeks postpartum. Peer groups will be expected to last approximately one hour. Each peer group will include 5-10 new mothers. A facilitator will be present for these groups, but the hope is to have mothers discuss with each other their postpartum experience and activities of their newborn at home.
Study: NCT00735345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy
Study: NCT02946853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy - defibrillator
Description: Insertion of device capable of providing biventricular pacing and cardiac defibrillation
Study: NCT00735345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 15 mg/m2/d i.v. d1-5, d29-33

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation during chemoradio-immunotherapy
Description: 39.6 Gy total dose
Study: NCT01759953

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Game
Description: InsuOnline game, on the web, in the player´s own time and rhythm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional CME
Description: In-classroom traditional learning session about insulin therapy for diabetes, using a presential short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
Study: NCT01571960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEO-D03 DNA vaccine
Description: Either a 0.3-mg (Group 1: study vaccine) or 3-mg dose (Groups 2 and 3: study vaccine) administered as a 1-mL IM injection into the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEO-D03 DNA vaccine
Description: Either a 0.3-mg (Group 1: study vaccine) or 3-mg dose (Groups 2 and 3: study vaccine) administered as a 1-mL IM injection into the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEO-D03 DNA vaccine
Description: Either a 0.3-mg (Group 1: study vaccine) or 3-mg dose (Groups 2 and 3: study vaccine) administered as a 1-mL IM injection into the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B (MVA62B) vaccine
Description: 1 x 10\^8-TCID50 dose of MVA62B vaccine, administered as a 1-mL IM injection into the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B (MVA62B) vaccine
Description: 1 x 10\^8-TCID50 dose of MVA62B vaccine, administered as a 1-mL IM injection into the deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B (MVA62B) vaccine
Description: 1 x 10\^8-TCID50 dose of MVA62B vaccine, administered as a 1-mL IM injection into the deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for GEO-D03 DNA
Description: Administered as a 1-mL IM injection into the deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for GEO-D03 DNA
Description: Administered as a 1-mL IM injection into the deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for GEO-D03 DNA
Description: Administered as a 1-mL IM injection into the deltoid

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MVA62B:
Description: Administered as a 1-mL IM injection into the deltoid
Study: NCT03789331

Intervention type: OTHER
Intervention: Anogenital distance measurement
Description: The women were kindly asked to lay down in the lithotomy position with their thighs at 45° to the examination table. A digital caliper (Mitutoyo 500-752-10 ABSOLUTE Digimatic Coolant Proof Caliper 0-150mm / 0-6, Mitutoyo Corporation, Japan) was used to measure anogenital distance.~Anogenital distance anus to clitoris: will be measured in centimeters from the anterior clitoral surface to the center of the anus.~Anogenital distance anus to fourchette: will be measured in centimeters from the posterior fourchette to the center of the anus.~Two investigators who were blind to the gynecological status of the women will measure each distance three times, and the mean value of the six measurements of each anogenital distance will be used.

Intervention type: OTHER
Intervention: Anogenital distance measurement
Description: The women were kindly asked to lay down in the lithotomy position with their thighs at 45° to the examination table. A digital caliper (Mitutoyo 500-752-10 ABSOLUTE Digimatic Coolant Proof Caliper 0-150mm / 0-6, Mitutoyo Corporation, Japan) was used to measure anogenital distance.~Anogenital distance anus to clitoris: will be measured in centimeters from the anterior clitoral surface to the center of the anus.~Anogenital distance anus to fourchette: will be measured in centimeters from the posterior fourchette to the center of the anus.~Two investigators who were blind to the gynecological status of the women will measure each distance three times, and the mean value of the six measurements of each anogenital distance will be used.
Study: NCT01653054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anal Pap Smear, HPV DNA Testing
Description: Anal Pap Smears and HPV DNA testing will be performed on all subjects.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anal Pap Smear, HPV DNA Testing
Description: Anal Pap Smears and HPV DNA testing will be performed on all subjects.
Study: NCT05538026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: daily dose of 3 g (2 g orally + 1 g rectally)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal transplantation
Description: Preparation of fresh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of UC patient by colonoscopy after standard bowel preparation.
Study: NCT02795364

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Structural Image Guidance
Description: Resecting the tumor in accordance with the margin on MRI T1W-enhanced delineation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metabolic Image Guidance
Description: Aggressive resecting of the tumor in accordance with the margin on MRS CNI delineation
Study: NCT03332043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIRREM
Description: HIRREM (Brain State Technologies, Scottsdale, AZ) is a closed-loop, allostatic, acoustic stimulation neurotechnology that uses software-guided algorithmic analysis to identify and translate selected brain frequencies into audible tones of varying pitch and timing, to support real-time self-optimization of brain activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambient Nature Sounds
Description: Digitally recordings of various ambient nature sounds such as a stream, waterfall, ocean waves, or rainfall, are provided via ear buds.
Study: NCT02906436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xvivo Chamber